U.S. Markets open in 6 hrs 19 mins

The Cassava Sciences Saga Rages On — Why This Alzheimer's Update Didn't Save It

·2 min read
The Cassava Sciences Saga Rages On — Why This Alzheimer's Update Didn't Save It
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Cassava said Wednesday that patients who received its experimental Alzheimer's drug showed improved cognition at a year. But SAVA stock dipped.